Oncolytics Biotech Inc(ONCY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONCY Oncolytics Biotech Inc

休市中 08-14 16:00:00 EDT

0.8340

+0.0340

+4.25%

盘后0.8050

-0.0290-3.48%

19:02 EDT

最高0.8460	最低0.7832	成交量112.70万
今开0.8000	昨收0.8000	日振幅7.85%
总市值1.06亿	流通市值1.03亿	总股本1.28亿
成交额92.36万	换手率0.91%	流通股本1.24亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.834,"timestamp":1786737600000,"preClose":0.8,"halted":0,"volume":1126966,"hourTrading":{"tag":"盘后","latestPrice":0.805,"preClose":0.834,"latestTime":"19:02 EDT","volume":4063,"amount":3279.553,"timestamp":1786748546656,"change":-0.029,"changeRate":-0.034772,"amplitude":0.034772},"delay":0,"changeRate":0.0424999999999999,"floatShares":124000000,"shares":127510505,"eps":-0.323929,"marketStatus":"休市中","change":0.034,"latestTime":"08-14 16:00:00 EDT","open":0.8,"high":0.846,"low":0.7832,"amount":923633.15945,"amplitude":0.0785,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.323929,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.8,"preHourTrading":{"tag":"盘前","latestPrice":0.815,"preClose":0.8,"latestTime":"09:19 EDT","volume":706,"amount":561.7786024,"timestamp":1786713545832,"change":0.015,"changeRate":0.01875,"amplitude":0.03125},"postHourTrading":{"tag":"盘后","latestPrice":0.805,"preClose":0.834,"latestTime":"19:02 EDT","volume":4063,"amount":3279.553,"timestamp":1786748546656,"change":-0.029,"changeRate":-0.034772,"amplitude":0.034772},"volumeRatio":1.677931560024415},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"1120027141","title":"Oncolytics Biotech® 旗下Pelareorep获二线及以后肛门癌适应症快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120027141","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120027141?lang=zh_cn&edition=full","pubTime":"2026-07-20 21:01","pubTimestamp":1784552476,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech® 宣布，其用于治疗二线及以后肛门癌的药物Pelareorep已获得快速通道资格认定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156217952","title":"Oncolytics Biotech：剩余33个Reo试验中心将于八月底前启动，以加速2026年下半年患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1156217952","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156217952?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:11","pubTimestamp":1783948283,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech宣布，为加速推进2026年下半年的患者招募工作，其剩余的33个Reo试验中心计划于八月底前全部启动。这一举措旨在提升试验效率，加快相关临床研究的整体进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160124056","title":"Oncolytics Biotech®宣布FDA监管里程碑及Ras突变MSS结直肠癌随机试验取得强劲临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1160124056","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160124056?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:11","pubTimestamp":1783948261,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech®宣布，其在针对Ras突变型微卫星稳定（MSS）结直肠癌的随机临床试验中，取得了美国食品药品监督管理局（FDA）的监管里程碑，并展现出强劲的临床进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177348668","title":"Oncolytics Biotech：Reo 33试验A部分肿瘤反应初步更新预计2026年底前公布；B部分招募或于2027年一季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1177348668","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177348668?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:08","pubTimestamp":1783948110,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc宣布，其Reo 33临床试验的A部分初步肿瘤反应数据更新，预计将在2026年年底前获得。与此同时，该试验的B部分患者招募工作，有望于2027年第一季度正式启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136116202","title":"Oncolytics Biotech：Reo 33临床半数试验点本月启动，超20名患者已预先确定","url":"https://stock-news.laohu8.com/highlight/detail?id=1136116202","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136116202?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:02","pubTimestamp":1783947740,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech公司宣布，其Reo 33临床研究项目将迎来关键进展。预计本月内，将有半数临床试验中心完成启动工作。与此同时，超过20名潜在患者已被预先识别，为后续的入组工作做好了充分准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179113225","title":"新闻发布：昂科利生物科技宣布史蒂夫·格洛弗加入董事会，并晋升约翰·麦卡多里为首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=1179113225","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179113225?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:03","pubTimestamp":1780405430,"startTime":"0","endTime":"0","summary":"圣地亚哥，2026年6月2日——临床阶段公司昂科利生物科技股份有限公司今日宣布，任命史蒂夫·格洛弗加入其董事会，并晋升约翰·麦卡多里为首席运营官。该公司致力于开发研究性、系统性活性的免疫疗法pelareorep，该疗法可促进潜在的保护性免疫反应，包括上调关键炎症细胞因子，从而形成三级淋巴结构并扩增肿瘤浸润淋巴细胞。昂科利正积极寻求战略合作伙伴关系，以加速开发并最大化商业影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4585","BK4232","ONCY","BK4139","XBI","BK4581","BK4588","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191269322","title":"Oncolytics Biotech®宣布任命Steve Glover为董事会成员并晋升John Mcadory为首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=1191269322","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191269322?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:02","pubTimestamp":1780405332,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech®今日宣布两项重要人事变动。Steve Glover被任命为公司董事会成员，其丰富的行业经验将为公司战略发展提供新的视角与支持。同时，公司内部擢升John Mcadory为首席运营官，他将负责监督日常运营活动，推动公司核心业务的高效执行。这两项任命旨在强化公司治理结构与运营领导力，以支持Oncolytics Biotech Inc未来的发展计划与目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120765792","title":"Oncolytics Biotech Inc：KRAS突变MSS型MCRC二线治疗反应持续时间较历史基准提升3-4倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765792","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120765792?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:09","pubTimestamp":1777900185,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc最新研究数据显示，针对KRAS突变的微卫星稳定型转移性结直肠癌患者的二线治疗，其治疗反应持续时间取得显著突破。与历史基准的4-6个月相比，当前疗法使患者反应持续时间实现3-4倍的提升。\n这一突破性进展为晚期结直肠癌治疗领域注入新希望。尤其对于携带KRAS突变且微卫星状态稳定的患者群体，传统治疗方案效果有限，新数据预示着靶向治疗策略的重要进展。\n研究结果凸显了Oncolytics Biotech在肿瘤免疫治疗领域的创新实力。该公司专注于开发溶瘤病毒疗法，此次数据进一步验证了其技术平台在难治性癌症治疗中的潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176989151","title":"Oncolytics Biotech Inc - Pelareorep联合疗法在二线KRAS突变MSS型结直肠癌中展现19.5个月中位缓解持续时间","url":"https://stock-news.laohu8.com/highlight/detail?id=1176989151","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176989151?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:08","pubTimestamp":1777900124,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc宣布，其核心候选药物pelareorep联合疗法在针对二线治疗KRAS突变、微卫星稳定（MSS）型转移性结直肠癌（mCRC）的临床试验中取得积极数据。研究结果显示，该联合治疗方案的中位缓解持续时间达到19.5个月，展现出持久的抗肿瘤活性。\n这一数据凸显了pelareorep在难治性结直肠癌患者群体中的治疗潜力，特别是针对KRAS突变这一常见且治疗挑战较大的亚型。较长的缓解持续时间可能为患者带来更显著的临床获益，也为后续临床开发提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100043313","title":"Oncolytics Biotech Inc 将开会讨论Pelareorep在二线及后线SCAC中的单臂关键研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1100043313","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100043313?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:02","pubTimestamp":1775480546,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc 宣布将召开会议，重点讨论其候选药物Pelareorep在二线及后线转移性结直肠腺癌（SCAC）患者中进行的单臂关键性研究。该研究旨在评估Pelareorep在这一难治患者群体中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177910860","title":"Oncolytics Biotech Inc 定于2026年4月16日就Pelareorep用于肛门癌适应症召开FDA C类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1177910860","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177910860?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:01","pubTimestamp":1775480480,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc (ONCY) 已安排于2026年4月16日与美国食品药品监督管理局（FDA）举行C类会议，会议核心议题将聚焦其候选药物Pelareorep在肛门癌领域的应用前景。此次会议旨在就相关研发路径与监管要求进行深入探讨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518700012","title":"加拿大皇家银行：维持Oncolytics Biotech(ONCY.US)评级，由优于大市调整至优于大市评级, 目标价由6.00美元调整至5.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518700012","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518700012?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:52","pubTimestamp":1741625543,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Oncolytics Biotech(ONCY.US)评级，由优于大市调整至优于大市评级, 目标价由6.00美元调整至5.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11005248641243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518713012","title":"Oncolytics Biotech Inc.盘中异动 早盘大幅下跌5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518713012","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518713012?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:52","pubTimestamp":1741614720,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时52分，Oncolytics Biotech Inc.股票出现波动，股价快速下挫5.59%。截至发稿，该股报0.650美元/股，成交量2.8965万股，换手率0.04%，振幅5.78%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2809.66%、628.56%、126.92%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021520198a2a262&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021520198a2a262&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCWF","ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109304519","title":"Oncolytics Biotech 2024财年GAAP每股收益(C$0.41)优于预期(C$0.42)，$1590万现金余量可支撑至2025年第三季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1109304519","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109304519?lang=zh_cn&edition=full","pubTime":"2025-03-07 20:12","pubTimestamp":1741349531,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech 报告季度每股亏损$，优于分析师预期的$，超出2.38%。这与去年同期持平。以上内容来自Benzinga Earnings专栏，原文如下：Oncolytics Biotech  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 2.38 percent. This is unchanged from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Oncolytics Biotech 2024财年GAAP每股收益(C$0.41)优于预期(C$0.42)，$1590万现金余量可支撑至2025年第三季度","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517660251","title":"Oncolytics Biotech Inc.盘中异动 早盘股价大跌5.12%报0.700美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517660251","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517660251?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:44","pubTimestamp":1741272275,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时44分，Oncolytics Biotech Inc.股票出现异动，股价大幅跳水5.12%。截至发稿，该股报0.700美元/股，成交量5.4394万股，换手率0.07%，振幅3.48%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1276.82%、263.37%、58.71%，振幅较大的相关个股有Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为31.46%、30.53%、23.72%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224435abeb7b5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224435abeb7b5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCY","BK4139","ONCWF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517940666","title":"Oncolytics Biotech Inc.盘中异动 快速拉升6.03%报0.689美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517940666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517940666?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:51","pubTimestamp":1741197100,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时51分，Oncolytics Biotech Inc.股票出现波动，股价急速拉升6.03%。截至发稿，该股报0.689美元/股，成交量5.0539万股，换手率0.07%，振幅4.60%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体涨幅为1.24%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nutriband Inc C/Wts 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为942.34%、304.49%、296.39%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306015140989d727e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306015140989d727e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCY","ONCWF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677970","title":"Oncolytics Biotech Inc.盘中异动 早盘股价大跌6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677970","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677970?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:31","pubTimestamp":1741098674,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时31分，Oncolytics Biotech Inc.股票出现波动，股价快速下挫6.49%。截至发稿，该股报0.620美元/股，成交量5.3039万股，换手率0.07%，振幅0.00%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Exicure, Inc.、Protagenic Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1047.69%、1024.96%、405.58%，振幅较大的相关个股有Orchestra Biomed Holdings, Inc.、Hoth Therapeutics, Inc.、Jasper Therapeutics, Inc.，振幅分别为5.85%、5.06%、4.84%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223114a25f03fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223114a25f03fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCWF","ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512806814","title":"Oncolytics Biotech Inc.盘中异动 快速跳水5.18%报0.717美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512806814","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512806814?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:36","pubTimestamp":1739986567,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日01时36分，Oncolytics Biotech Inc.股票出现异动，股价快速下跌5.18%。截至发稿，该股报0.717美元/股，成交量23.1895万股，换手率0.30%，振幅5.29%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体涨幅为0.45%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013607988b4f34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013607988b4f34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCWF","BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510866634","title":"Oncolytics Biotech Inc.盘中异动 早盘急速下挫5.10%报0.737美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510866634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510866634?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:06","pubTimestamp":1739200002,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日23时06分，Oncolytics Biotech Inc.股票出现波动，股价大幅下跌5.10%。截至发稿，该股报0.737美元/股，成交量11.9788万股，换手率0.16%，振幅6.44%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体涨幅为0.20%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210230642abc9ad8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210230642abc9ad8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCY","ONCWF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509272987","title":"Oncolytics Biotech Inc.盘中异动 快速上涨5.23%报0.779美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509272987","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509272987?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:32","pubTimestamp":1738852321,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时32分，Oncolytics Biotech Inc.股票出现异动，股价大幅上涨5.23%。截至发稿，该股报0.779美元/股，成交量34.0492万股，换手率0.44%，振幅2.70%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223201a23bce41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223201a23bce41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCY","BK4139","ONCWF"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":0.0393},{"period":"1month","weight":-0.0774},{"period":"3month","weight":-0.0188},{"period":"6month","weight":-0.2132},{"period":"1year","weight":-0.113},{"period":"ytd","weight":-0.0458}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Oncolytics Biotech Inc.于1998年4月2日根据亚伯达法律以亚伯达有限责任公司的名字成立，并于2026年4月1日在内华达州重新注册成立。该公司是一家临床阶段的生物制药公司，正在开发pelareorep，这是一种静脉给药的免疫治疗药物，旨在选择性地在RAS突变的肿瘤中复制并激活免疫反应。该公司尚未实现盈利，需要额外融资以维持运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.123611},{"month":4,"riseRate":0.75,"avgChangeRate":0.024604},{"month":5,"riseRate":0.375,"avgChangeRate":0.014597},{"month":6,"riseRate":0.25,"avgChangeRate":0.155922},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.014421},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.070235},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Oncolytics Biotech Inc(ONCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Oncolytics Biotech Inc(ONCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}